Latest Insider Transactions at Anaptysbio, Inc (ANAB)
This section provides a real-time view of insider transactions for Anaptysbio, Inc (ANAB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ANAPTYSBIO, INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ANAPTYSBIO, INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 29
2024
|
Hollings Renton |
SELL
Open market or private sale
|
Direct |
10,000
-83.68%
|
$250,000
$25.0 P/Share
|
|
Nov 29
2024
|
Hollings Renton |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+45.56%
|
$60,000
$6.93 P/Share
|
|
Sep 23
2024
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,500
-8.88%
|
$57,000
$38.67 P/Share
|
|
Sep 23
2024
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+8.15%
|
$27,000
$18.5 P/Share
|
|
Sep 17
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,780
-53.85%
|
$143,640
$38.41 P/Share
|
|
Sep 16
2024
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
12,220
-49.85%
|
$476,580
$39.53 P/Share
|
|
Sep 16
2024
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+40.41%
|
$200,000
$20.16 P/Share
|
|
Sep 16
2024
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,220
-12.6%
|
$84,360
$38.93 P/Share
|
|
Sep 16
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,720
-34.37%
|
$340,080
$39.53 P/Share
|
|
Sep 16
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+27.0%
|
$70,000
$14.02 P/Share
|
|
Sep 15
2024
|
John A Orwin |
BUY
Exercise of conversion of derivative security
|
Direct |
1,300
+28.05%
|
-
|
|
Sep 14
2024
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+46.28%
|
-
|
|
Sep 14
2024
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+25.4%
|
-
|
|
Sep 14
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+35.84%
|
-
|
|
Aug 14
2024
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,000
-14.69%
|
$80,000
$40.0 P/Share
|
|
Aug 14
2024
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+12.81%
|
$36,000
$18.5 P/Share
|
|
Aug 14
2024
|
Eco R1 Capital, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
273,972
+3.4%
|
$9,862,992
$36.5 P/Share
|
|
Jul 18
2024
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,500
-11.43%
|
$52,500
$35.0 P/Share
|
|
Jul 18
2024
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+10.26%
|
$27,000
$18.5 P/Share
|
|
Jul 15
2024
|
Hollings Renton |
SELL
Open market or private sale
|
Direct |
10,000
-59.6%
|
$300,000
$30.74 P/Share
|
|
Jul 15
2024
|
Hollings Renton |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+45.56%
|
$60,000
$6.93 P/Share
|
|
Jun 21
2024
|
Dennis M Fenton |
SELL
Open market or private sale
|
Direct |
1,950
-50.0%
|
$44,850
$23.17 P/Share
|
|
Jun 18
2024
|
Hollings Renton |
SELL
Open market or private sale
|
Direct |
1,950
-50.0%
|
$44,850
$23.16 P/Share
|
|
Jun 15
2024
|
Hollings Renton |
BUY
Exercise of conversion of derivative security
|
Direct |
3,900
+50.0%
|
-
|
|
Jun 15
2024
|
John A Orwin |
BUY
Exercise of conversion of derivative security
|
Direct |
2,035
+50.0%
|
-
|
|
Jun 15
2024
|
J. Anthony Ware |
BUY
Exercise of conversion of derivative security
|
Direct |
3,900
+34.21%
|
-
|
|
Jun 15
2024
|
John P. Schmid |
BUY
Exercise of conversion of derivative security
|
Direct |
3,900
+50.0%
|
-
|
|
Jun 15
2024
|
Magda Marquet |
BUY
Exercise of conversion of derivative security
|
Direct |
3,900
+50.0%
|
-
|
|
Jun 15
2024
|
Dennis M Fenton |
BUY
Exercise of conversion of derivative security
|
Direct |
3,900
+50.0%
|
-
|
|
Jun 15
2024
|
Rita Jain |
BUY
Exercise of conversion of derivative security
|
Direct |
4,534
+50.0%
|
-
|
|
May 22
2024
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-60.88%
|
$34,500
$23.72 P/Share
|
|
Mar 26
2024
|
Daniel Faga CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
347,441
-46.38%
|
$7,296,261
$21.6 P/Share
|
|
Mar 25
2024
|
Daniel Faga CEO |
SELL
Open market or private sale
|
Direct |
3,000
-0.4%
|
$63,000
$21.42 P/Share
|
|
Mar 22
2024
|
Daniel Faga CEO |
SELL
Open market or private sale
|
Direct |
145,940
-16.25%
|
$3,210,680
$22.78 P/Share
|
|
Feb 16
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-60.68%
|
$125,000
$25.0 P/Share
|
|
Feb 16
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+37.76%
|
$70,000
$14.02 P/Share
|
|
Jan 30
2024
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,065
-76.07%
|
$70,495
$23.63 P/Share
|
|
Jan 08
2024
|
Daniel Faga CEO |
SELL
Open market or private sale
|
Direct |
6,866
-0.76%
|
$144,186
$21.81 P/Share
|
|
Jan 08
2024
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,180
-35.11%
|
$45,780
$21.81 P/Share
|
|
Jan 08
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,305
-41.57%
|
$48,405
$21.81 P/Share
|
|
Jan 08
2024
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,554
-20.15%
|
$53,634
$21.81 P/Share
|
|
Jan 06
2024
|
Daniel Faga CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,850
+1.93%
|
-
|
|
Jan 06
2024
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,245
+45.79%
|
-
|
|
Jan 06
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,545
+50.0%
|
-
|
|
Jan 06
2024
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,145
+32.66%
|
-
|
|
Nov 22
2023
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
882
-100.0%
|
$12,348
$14.19 P/Share
|
|
Sep 18
2023
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,895
-80.16%
|
$74,005
$19.32 P/Share
|
|
Sep 18
2023
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,895
-81.54%
|
$74,005
$19.32 P/Share
|
|
Sep 14
2023
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,105
-24.39%
|
$39,995
$19.48 P/Share
|
|
Sep 14
2023
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+41.01%
|
-
|